RHYTHM PHARMACEUTICALS, INC. (RYTM)
$107.17-$5.36 (-4.76%) Today
Yann Mazabraud - OfficerYann Mazabraud - OfficerRhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 13 | 182,676 | $20.75M |
| Grant or award | 12 | 105,075 | |
| Option exercise | 22 | 340,510 | |
| Tax withholding / forfeiture | 1 | 2,150 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
67 Form 4 filings on record, the earliest from Nov 8, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jennifer L. Good - Director | Option exercise | Common Stock | 4,000 | - | - | |
| Jennifer L. Good - Director | Option exercise | Restricted Stock Units | 4,000 | $0.00 | - | |
| David W. J. McGirr - Director | Option exercise | Common Stock | 4,000 | - | - | |
| David W. J. McGirr - Director | Option exercise | Restricted Stock Units | 4,000 | $0.00 | - | |
| Christopher Paul German - Officer | Option exercise | Common Stock | 1,069 | $17.97 | $19K | |
| Christopher Paul German - Officer | Open-market sale | Common Stock | 2,069 | $67.19 | $139K | |
| Christopher Paul German - Officer | Option exercise | Stock Options (Right to Buy) | 1,069 | $0.00 | - | |
| David W. J. McGirr - Director | Option exercise | Common Stock | 65,431 | $4.59 | $300K | |
| David W. J. McGirr - Director | Open-market sale | Common Stock | 55,558 | $65.15 | $3.62M | |
| David W. J. McGirr - Director | Open-market sale | Common Stock | 9,873 | $65.64 | $648K | |
| David W. J. McGirr - Director | Option exercise | Stock Option (Right to Buy) | 65,431 | $0.00 | - | |
| Jennifer Kayden Lee - Officer | Option exercise | Common Stock | 20,622 | $6.80 | $140K | |
| Jennifer Kayden Lee - Officer | Option exercise | Common Stock | 28,717 | $24.29 | $698K | |
| Jennifer Kayden Lee - Officer | Option exercise | Common Stock | 11,642 | $30.66 | $357K | |
| Jennifer Kayden Lee - Officer | Open-market sale | Common Stock | 38,051 | $65.68 | $2.50M | |
| Jennifer Kayden Lee - Officer | Open-market sale | Common Stock | 17,540 | $66.95 | $1.17M | |
| Jennifer Kayden Lee - Officer | Open-market sale | Common Stock | 11,070 | $67.56 | $748K | |
| Jennifer Kayden Lee - Officer | Open-market sale | Common Stock | 200 | $68.43 | $14K | |
| Jennifer Kayden Lee - Officer | Option exercise | Stock Option (Right to Buy) | 20,622 | $0.00 | - | |
| Jennifer Kayden Lee - Officer | Option exercise | Stock Option (Right to Buy) | 28,717 | $0.00 | - | |
| Jennifer Kayden Lee - Officer | Option exercise | Stock Option (Right to Buy) | 11,642 | $0.00 | - | |
| Joseph Shulman - Officer | Option exercise | Common Stock | 7,969 | $6.80 | $54K | |
| Joseph Shulman - Officer | Option exercise | Common Stock | 5,312 | $21.38 | $114K | |
| Joseph Shulman - Officer | Open-market sale | Common Stock | 6,604 | $65.73 | $434K | |
| Joseph Shulman - Officer | Open-market sale | Common Stock | 5,977 | $67.05 | $401K | |
| Joseph Shulman - Officer | Open-market sale | Common Stock | 700 | $67.83 | $47K | |
| Joseph Shulman - Officer | Option exercise | Stock Option (right to buy) | 7,969 | $0.00 | - | |
| Joseph Shulman - Officer | Option exercise | Stock Option (right to buy) | 5,312 | $0.00 | - | |
| Pamela J. Cramer - Officer | Option exercise | Common Stock | 4,687 | $19.02 | $89K | |
| Pamela J. Cramer - Officer | Open-market sale | Common Stock | 4,687 | $60.00 | $281K | |
| Pamela J. Cramer - Officer | Option exercise | Common Stock | 4,688 | $19.02 | $89K | |
| Pamela J. Cramer - Officer | Open-market sale | Common Stock | 4,688 | $65.00 | $305K | |
| Pamela J. Cramer - Officer | Option exercise | Stock Options (Right to buy) | 4,687 | $0.00 | - | |
| Pamela J. Cramer - Officer | Option exercise | Stock Options (Right to buy) | 4,688 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 67 RYTM filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JOSEPH J SHULMAN | Officer | 5,079 | $597K | View on EDGAR | |
| ALASTAIR GARFIELD | Officer | 7,763 | $913K | View on EDGAR | |
| Jennifer Kayden Lee | Officer | 75,834 | $8.92M | View on EDGAR |
RHYTHM PHARMACEUTICALS, INC. (RYTM) had 12 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for RYTM runs to 67 Form 4 filings, the earliest from 2024-11-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RYTM were filed in the last 90 days.
13 insider sales of RYTM were filed in the last 90 days, totaling $20.75M.
This page tracks RYTM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RYTM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
